BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BioXcel Therapeutics announced FDA acceptance of its supplemental New Drug Application (sNDA) for IGALMI® to be used in an at-home setting for acute agitation in bipolar disorder and schizophrenia, with a PDUFA date set for November 14, 2026. The company is advancing late-stage clinical trials for BXCL501 in agitation associated with Alzheimer's de…